RECORD:It is finally confirmed that Rosiglitazone does not increase the diabetic cardiovascular death risk
- VernacularTitle:罗格列酮不增加糖尿病患者心血管病死亡风险——RECORD研究最终证实
- Author:
Dalong ZHU
- Publication Type:Journal Article
- Keywords:
type 2 diabetes;
Rosiglitazone;
cardiovascular death
- From:
Chinese Journal of Practical Internal Medicine
2003;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
The aim of RECORD study is to compare the time of first hospitalization due to cardiovascular events or death between patients treated with Metformine+ Rosinglitazone,Sulfonylureas+ Rosinglitazone with those treated with Metformine+Sulfonylureas.The result showed that,after treated equally for 5.5 years,there was no difference in the time of first hospitalization due to cardiovascular events or death between the two groups.The blood glucose control,as indicated by average HbA1c,was improved in Rosinglitazone group compared with that in the control group.
